Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apa/Enza Short Study: Shortened 12 Months Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Low Volume Castration-sensitive Prostate Cancer: a Randomized Nationwide Study

NCT07260435 is registered in ClinicalTrials.gov with Nick Beije as lead sponsor.

NCT NCT07260435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07260435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apa/Enza Short Study: Shortened 12 Months Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Low Volume Castration-sensitive Prostate Cancer: a Randomized Nationwide Study
Lead sponsor
Nick Beije
Phase
Phase 3
Overall status
Recruiting
Start date
February 20, 2024
Completion date
December 31, 2027
Enrollment
400 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer